Hikal Limited — Investor Meet, 18-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Hikal Ltd. reported Q2 FY25 revenue of INR 453 crores, reflecting a 29% growth year-over-year (YoY) and on a quarter-on-quarter (QoQ) basis. EBITDA for the quarter stood at INR 75 crores, achieving a robust 30% YoY increase, leading to an EBITDA margin of 16.5%, up from 13.2% last year. For H1 FY25, total revenue reached INR 860 crores, an increase of 23% YoY. The company achieved a working capital reduction of INR 50 crores, enhancing cash flow.

2. Future Outlook and Growth Drivers: Management expressed optimism about sustained growth, particularly driven by new customer acquisitions and project initiatives within the Pharmaceutical sector. The Animal Health business is poised for expansion, with significant product validations and upcoming regulatory filings expected to accelerate market entries.

3. Order Book and Operational Updates: The order book remains strong, particularly in the Pharmaceutical division, bolstered by a favorable China + 1 strategy. Expected ramp-up in production and sales from new assets should enhance operational efficiency moving forward.

4. Analyst Q&A Insights (Detailed):

- Revenue and Profitability: Analysts sought insight into future revenue growth in the Pharmaceutical segment, with management indicating steady volume growth and new launches anticipated to drive momentum in Q4.

- Market Position and Competitive Landscape: Queries related to competitive pressures and market positioning were addressed, with management highlighting a focus on niche products to counter competitive pricing from Chinese firms.

- Operational Challenges or Risks: Concerns regarding supply chain disruptions were acknowledged, but management expressed confidence in their operational strategies and improved cost controls.

- Capex and Capital Allocation: Analysts inquired about capital expenditure (capex) plans, with management confirming ongoing investment primarily in the Pharmaceutical division, while managing existing debt levels comfortably around INR 800 crores.

- Strategic Priorities and Long-Term Vision: The company emphasized a commitment to innovation, talent development, and sustainability as critical elements shaping their long-term strategy.

5. Market or Regulatory Updates: There was a discussion on regulatory developments affecting the Animal Health segment, with commercial product launches anticipated following validation processes.

6. Strategic Focus Areas: Management is prioritizing new product developments, operational efficiencies, and strategic customer engagements to navigate market dynamics and enhance growth.

7. Investor Insight: The growth trajectory, strong financials, and proactive management responses suggest a favorable outlook. Current indicators and strategic plans are aligned for a potential 'buy' stance as Hikal navigates through upcoming opportunities, especially in Pharma and Animal Health sectors.